Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $19.05
Previous CloseN/A
Volume311.62K
Average Volume (3M)587.89K
Market Cap
$170.32M
Enterprise Value$679.32M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
May 14, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding74,051,840
10 Day Avg. Volume566,573
30 Day Avg. Volume587,891
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)139.61
Price to Cash Flow (P/CF)12.70
P/FCF Ratio0.00
Enterprise Value/Market Cap3.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit473.72
Enterprise Value/Ebitda-15.07
Forecast
1Y Price Target
$14.20Price Target Upside545.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Efficacy DataVMT01/02 demonstrated high response rates in multiple tested models and over 70% complete and durable response when combined with PD1 immunotherapy.
Financial OutlookCATX reported a preliminary estimated unaudited cash position of approximately $227.8 million, which is expected to fund operations into late 2026.
Therapeutic AdvancementsThe combination of VMT01 and nivolumab is expected to amplify the therapeutic impact.
Bears Say
Competitive PositionThe data improves on previous responses, though responses are still slightly trailing behind competitors, especially given the unconfirmed nature of the two responses.
Financial ChallengesYears of cash left is less than 2.0.
Market SentimentShort interest as a percentage of float is 11.1%.
---
Ownership Overview
3.24% Insiders
19.25% Mutual Funds
20.65% Other Institutional Investors
51.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.22 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $170.32M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 45 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Mar 26, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.268 by -$0.302.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,051,840 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.268. Following the earnings report the stock price went up 1.322%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
---
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.20 (545.45% Upside)
$14.20 (545.45% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.83%
12-Months-Change
Fundamentals
Return on Equity
-19.42%
Trailing 12-Months
Asset Growth
253.93%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics (CATX) is a biotechnology company focused on developing therapies for cancer treatment. The company operates in the healthcare sector, specifically within the pharmaceutical and biotechnology industries. Its core products include innovative therapeutic solutions aimed at improving the efficacy and safety of cancer treatments through advanced technology and research.
---
CATX Stock 12 Month Forecast
Average Price Target
$14.20
▲(545.45% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
+0.19%
reiterated a buy rating 3 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of +0.19% per trade.
---